Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients

被引:81
作者
Kim, Jung Mogg
Kim, Joo Sung
Kim, Nayoung
Kim, Sang Gyun
Jung, Hyun Chae
Song, In Sung
机构
[1] Hanyang Univ, Coll Med, Dept Microbiol, Seoul 133791, South Korea
[2] Hanyang Univ, Coll Med, Inst Biomed Sci, Seoul 133791, South Korea
[3] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea
[4] Seoul Natl Univ, Coll Med, Liver Res Inst, Seoul 110744, South Korea
关键词
antimicrobial resistance; MIC; multidrug resistance;
D O I
10.1016/j.ijantimicag.2006.02.015
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In this study we assessed minimum inhibitory concentration (MIC) values and resistance rates of several antibiotics in 65 primary and 324 secondary Helicobacter pylori isolates from Korean patients. Primary resistance to amoxicillin, clarithromycin, metronidazole, tetracycline, azithromycin, ciprofloxacin, levofloxacin and moxifloxacin was 18.5%, 13.8%, 66.2%, 12.3%, 32.3%, 33.8%, 21.5% and 21.5%, respectively. Secondary resistance was 31.3%, 85.1%, 70.1%, 0%, 89.6%, 35.8%, 32.8% and 32.8%, respectively. Sequence analysis of pbp1A in H. pylori strains with an amoxicillin MIC >= 2 mu g/mL revealed C206T (Asp69 -> Val), C1667G (Thr556 -> Ser), A1684T (Asn562 -> Tyr), A1777G (Thr593 -> Ala) and C I 798A (Pro600 -> Thr) substitutions. Eleven (16.4%) of 67 treatment failures showed mixed infections with antibiotic-susceptible and -resistant H. pylori. The most common multidrug resistance profile was to clarithromycin, metronidazole and azithromycin. These results indicate that MIC values of secondary isolates were higher than those of primary isolates and that resistance to amoxicillin is probably mediated through mutations in pbp1A. (c) 2006 Elsevier B.V and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:6 / 13
页数:8
相关论文
共 35 条
[1]   Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin -: Influence on treatment outcome [J].
Adamek, RJ ;
Suerbaum, S ;
Pfaffenbach, B ;
Opferkuch, W .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (03) :386-389
[2]  
[Anonymous], 2002, M100S12 NCCLS
[3]   The status of antimicrobial resistance of Helicobacter pylori in eastern Europe [J].
Boyanova, L ;
Mentis, A ;
Gubina, M ;
Rozynek, E ;
Gosciniak, G ;
Kalenic, S ;
Göral, V ;
Kupcinskas, L ;
Kantarçeken, B ;
Aydin, A ;
Archimandritis, A ;
Dzierzanowska, D ;
Vcev, A ;
Ivanova, K ;
Marina, M ;
Mitov, I ;
Petrov, P ;
Özden, A ;
Popova, M .
CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (07) :388-396
[4]   Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999) [J].
Cabrita, J ;
Oleastro, M ;
Matos, R ;
Manhente, A ;
Cabral, J ;
Barros, R ;
Lopes, AI ;
Ramalho, P ;
Neves, BC ;
Guerreiro, AS .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (06) :1029-1031
[5]  
Cheon Jae Hee, 2005, Korean J Gastroenterol, V45, P111
[6]   Characterization of an in vitro-selected amoxicillin-resistant strain of Helicobacter pylori [J].
DeLoney, CR ;
Schiller, NL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) :3368-3373
[7]   Helicobacter pylori [J].
Dunn, BE ;
Cohen, H ;
Blaser, MJ .
CLINICAL MICROBIOLOGY REVIEWS, 1997, 10 (04) :720-+
[8]   Alterations in penicillin-binding protein 1A confer resistance to β-lactam antibiotics in Helicobacter pylori [J].
Gerrits, MM ;
Schuijffel, D ;
van Zwet, AA ;
Kuipers, EJ ;
Vandenbroucke-Grauls, CMJE ;
Kusters, JG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (07) :2229-2233
[9]   European Multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori [J].
Glupczynski, Y ;
Mégraud, F ;
Lopez-Brea, M ;
Andersen, LP .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2001, 20 (11) :820-823
[10]  
GLUPCZYNSKI Y, 1990, AM J GASTROENTEROL, V85, P1545